Please click here for Important Safety Information.

Straight to the point—Exclusive microneedle delivery system redefines the vaccine experience

Helps protect against 2 A and 2 B influenza strains

Order today for patients 18 through 64 years of age.

Page 1 of 5

Straight to the point— A reliable administration process designed specifically for you1,2

Benefits of intradermal administration

Please click here for Important Safety Information.

Designed to simplify vaccine administration1,3

Microneedle delivery system1

• Delivers an accurate dose of antigen into the dermal layer regardless of a patient’s race, gender, or weight3

• Simplifies the administration process because you don’t need to choose among different needle sizes3

Prefilled1

• Saves time because there is no need to draw vaccine and no air purging required1

• Minimizes the likelihood of making a dosing error2,3

Designed to have fewer steps1

Affixed microneedle1

• Simplifies preparation because there is no need to attach needle1

CPT®a Code: 90630

90% smaller needle (1.5 mm microneedle)2,4

• Reduces the possibility of damage to nerves and blood vessels2

a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

Integrated needle shield1,2

• Completely covers the needle when activated

Designed with your needs in mind1,2

Page 2 of 5

Intradermal injection—works by utilizing the skin1,b

Visit Fluzone.com—support beyond immunization. See administration video.

Scan with your smartphone to see the microneedle in action or go to Fluzone.com/ID

Redness without a wheal. Redness with a wheal.

Injection-site expectationsBecause immune response occurs under the surface of the skin, redness and swelling at the injection site can be expected.1 Reactions usually resolve in 3 to 7 days.7

Wheal with no redness.

Please click here for Important Safety Information.

Illustrations are for visual reference only. Injection-site reactions can vary for each patient.

b A study investigating skin thickness at usual areas for intradermal vaccination found that the mean skin thickness at the deltoid was between 1.9 mm and 2.4 mm.6

• The skin, rich in dendritic cells, is the body’s first line of defense against infection3,5

• Dendritic cells capture antigens and activate a robust immune response3

Images not drawn to scale.= dendritic cell.

Epidermis = 0.12 mm

Dermis = 2 mm

Subcutaneous tissue

Connective tissue

Muscle

Page 3 of 5

Reserve for the 2015-2016 influenza seasonTo order Fluzone Intradermal Quadrivalent vaccine or to learn more about the Fluzone Partners Program, log onto VaccineShoppe.com® or call 1-800-VACCINE (1-800-822-2463).

Fluzone Intradermal Quadrivalent vaccine— safety profileFrequency of solicited injection-site reactions and systemic adverse events (AEs) within 7 days post-vaccination1

Please see full Prescribing Information for additional safety data, including rates of solicited AEs by intensity category.

• Injection-site reactions were more frequent with the intradermal vaccine with the exception of pain, which was similar1

• Generally, reactions were mild to moderate in intensity and resolved in 3 to 7 days7 • Unsolicited adverse reaction profile of Fluzone Intradermal Quadrivalent vaccine

was similar to that of Fluzone Intradermal vaccine1

c N is the number of vaccinated participants with available data for the events listed. d TIV-ID1: 2012-2013 trivalent Fluzone Intradermal vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and

B/Texas/6/2011 (Yamagata lineage), licensed. e TIV-ID2: Trivalent Investigational Intradermal vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Brisbane/60/2008

(Victoria lineage), non-licensed.f Fever measured by any route.

Fluzone Intradermal

Quadrivalent Vaccine

(Nc=1649-1656)

TIV-ID1d

(B Yamagata)(Nc=819-820)

TIV-ID2e

(B Victoria)(Nc=836-838)

Injection-site adverse reactions

Pain 53% 48% 50%

Pruritus 52% 45% 45%

Erythema 37% 34% 32%

Swelling 20% 15% 15%

Induration 17% 14% 11%

Ecchymosis 3% 2% 2%

Systemic adverse reactions

Myalgia 34% 29% 31%

Headache 33% 31% 33%

Malaise 28% 26% 30%

Shivering 12% 10% 11%

Fever (≥100.4°F)f 1% 1% 1%

Page 4 of 5

FLUZONE PARTNERS PROGRAMFLUZONE HIGH-DOSE

VACCINE

FLUZONE INTRADERMAL

QUADRIVALENT VACCINE

FLUZONE QUADRIVALENT

VACCINE

References: 1. Fluzone Intradermal Quadrivalent vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2014. 2. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007;25:8833-8842. 3. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26:3197-3208. 4. Immunization Action Coalition. Administering vaccines: dose, route, site, and needle size. http://www.immunize.org/catg.d/p3085.pdf. Accessed November 17, 2014. 5. Nestle FO, Nickoloff BJ. Deepening our understanding of immune sentinels in the skin. J Clin Invest. 2007;117:2382-2385. 6. Laurent A, Mistretta F, Bottigioli D, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine. 2007;25:6423-6430. 7. Sanofi Pasteur Inc. Data on file (Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years). January 2014. MKT28928.

SANOFI PASTEUR. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofipasteur.usMKT28885-1 © 2015 Sanofi Pasteur Inc. 1/15

IMPORTANT SAFETY INFORMATION

INDICATIONFluzone Intradermal Quadrivalent vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Fluzone Intradermal Quadrivalent vaccine is approved for use in persons 18 through 64 years of age.

SAFETY INFORMATIONThe most common local reactions to Fluzone Intradermal Quadrivalent vaccine include pruritus, erythema, swelling, and induration at the injection site. Such reactions occurred more frequently with trivalent Fluzone Intradermal vaccine than with trivalent Fluzone vaccine. Other adverse reactions to Fluzone Intradermal Quadrivalent vaccine include pain at the injection site; myalgia, headache, and malaise. Other adverse reactions may occur.

Fluzone Intradermal Quadrivalent vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Intradermal Quadrivalent vaccine should be based on careful consideration of the potential benefits and risks. Vaccination with Fluzone Intradermal Quadrivalent vaccine may not protect all individuals.

Before administering Fluzone Intradermal Quadrivalent vaccine, please click here for full Prescribing Information.

To order Fluzone Intradermal Quadrivalent vaccine or to learn about the Fluzone Partners Program, please log onto VaccineShoppe.com or call 1-800-VACCINE (1-800-822-2463).

Fluzone Intradermal and Fluzone Intradermal Quadrivalent vaccines are manufactured and distributed by Sanofi Pasteur Inc.

Page 5 of 5